Abstract

Objective: To study the pattern and cell type-specificity of collagenase 3, membrane-type 1 matrix metalloproteinase (MT1-MMP), and gelatinase A mRNA expression in the synovial membrane in rheumatoid arthritis (RA). Methods:...

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A Theoretical Model of Type I Collagen Proteolysis by Matrix Metalloproteinase (MMP) 2 and Membrane Type 1 MMP in the Presence of Tissue Inhibitor of Metalloproteinase 2
Emmanouil D Karagiannis ... Aleksander S Popel
Journal of Biological Chemistry | VOL. 279
Emmanouil D Karagiannis, et. al.Emmanouil D Karagiannis ... Aleksander S Popel
01 Sep 2004
Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis.
Thomas Pap ... Steffen Gay
Arthritis & Rheumatism | VOL. 43
Thomas Pap, et. al.Thomas Pap ... Steffen Gay
01 Jun 2000
An Alternative Processing of Integrin αv Subunit in Tumor Cells by Membrane Type-1 Matrix Metalloproteinase
Boris I Ratnikov ... Alex Y Strongin
Journal of Biological Chemistry | VOL. 277
Boris I Ratnikov, et. al.Boris I Ratnikov ... Alex Y Strongin
01 Mar 2002
Modulation of the Membrane Type 1 Matrix Metalloproteinase Cytoplasmic Tail Enhances Tumor Cell Invasion and Proliferation in Three-dimensional Collagen Matrices
Natalie M Moss ... M Sharon Stack
Journal of Biological Chemistry | VOL. 284
Natalie M Moss, et. al.Natalie M Moss ... M Sharon Stack
01 Jul 2009
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.